What’s the Difference Between GLP-1 and GLP-1/GIP Medications?

For several years now, GLP-1 medications have been grabbing headlines for weight loss. Expanding what’s possible for adults struggling with obesity or excess weight-related health conditions, these drugs target hormones that regulate appetite, satiety, and metabolism.

With multiple options on the market, it can be hard to understand the differences between a standard GLP-1 receptor agonist and a GLP-1/GIP combo. The science behind these therapies is fascinating, albeit a little confusing. Let’s break down how they work, who they’re intended for, and when they might fit into your weight loss strategy.

What is a GLP-1 RA?

A GLP-1 receptor agonist (GLP-1 RA) is a type of medication that mimics a naturally occurring hormone in your body called glucagon-like peptide-1 (GLP-1). GLP-1 is produced in the gut after eating and manages several metabolic processes: it signals the pancreas to release insulin when blood sugar rises, reduces glucagon secretion (a hormone that increases blood sugar), slows stomach emptying, and communicates with the brain to promote feelings of fullness. Naturally-produced GLP-1 helps your body handle food more efficiently while regulating appetite.

GLP-1 RAs were originally developed for treating type 2 diabetes, but higher-dose versions are approved specifically for weight management in adults with obesity or those carrying excess weight with related health conditions. By slowing digestion and enhancing satiety, patients consume fewer calories without feeling deprived. Over time, this can lead to weight loss as well as improvements in blood sugar, cholesterol, blood pressure, and even markers of inflammation.

Currently available GLP-1 RAs for weight loss include Liraglutide (Saxenda) and Semaglutide (Wegovy). Liraglutide, taken daily, has been shown in clinical trials to help adults with obesity lose about 8% of their starting weight over a year compared with 2-3% on placebo.¹ Semaglutide, administered weekly, produces even more dramatic results, with patients losing 10-20% of their body weight over a similar timeframe.²

In clinical studies, semaglutide can appear more effective for weight loss than liraglutide, but in real-world settings, the impact depends on multiple factors, including individual metabolism, diet, activity level, adherence, and tolerance of side effects.

Research also suggests that GLP-1 RAs may support heart health, liver function, and even neurological conditions, in addition to their weight-loss capabilities.³ Compounded benefits of these medications are possible due to:

• Improved insulin sensitivity and blood sugar control to reduce cardiovascular strain
• Reductions in fat mass, particularly dangerous visceral fat (the deep midsection fat surrounding internal organs)
• Lower inflammation and metabolic stress on organs like the liver
• Influence on brain activity that regulates appetite and energy metabolism

Because GLP-1 receptors are active in the brain, scientists are exploring in greater detail how these medications may influence inflammation, insulin signaling, and cellular stress within the nervous system. Preliminary studies have prompted interest in the potential for affecting neurodegenerative and substance use disorders, though this research is still evolving and not part of standard clinical use. It’s fascinating to see where this research is heading, and it highlights how medications originally designed for metabolic health may influence broader systems in the body through shared hormonal and neurological pathways.³

What is a GLP-1 RA/GIP Dual-Agonist?

A GLP-1/GIP dual-agonist medication builds on the same foundation as a GLP-1 RA, but adds a second hormone into the mix: glucose-dependent insulinotropic polypeptide (GIP). Like GLP-1, GIP is a naturally occurring incretin hormone released from the gut after eating that affects insulin secretion, appetite signaling, and caloric energy expenditure.

A dual-agonist medication activates both GLP-1 and GIP receptors simultaneously, eliciting a broader metabolic response than GLP-1 alone; two complementary mechanisms target two distinct hormonal pathways. GLP-1 continues to slow gastric emptying, increase satiety, and reduce glucagon release, while GIP enhances insulin response and appears to act on brain centers involved in the processing, storage, and expenditure of calories at the cellular level. Signals of fullness and metabolic efficiency are amplified by the combination, and can lead to greater weight loss for some individuals compared with single-hormone therapies.⁴

Currently, the primary GLP-1/GIP medication approved for chronic weight management is tirzepatide (Zepbound). In research trials, adults with obesity taking tirzepatide lost an average of 15-21% of their body weight over 72 weeks (depending on dose) compared with about 3% in the placebo group. Many participants also saw improvements in waist circumference, blood pressure, cholesterol levels, and other cardiometabolic markers.⁵

Impressive research still warrants a little caution. Even though results imply a “better” medication, response to GLP-1/GIP dual-agonist therapy still varies from person to person. Some individuals experience significant appetite suppression and metabolic improvement, while others see more modest changes or have difficulty tolerating higher doses due to gastrointestinal side effects. Variability in effectiveness reflects unique physiological differences in things like gut hormone signaling, genetics, underlying metabolic health, and how the brain responds to appetite cues. Research studies are ultra-controlled, and have a hard time incorporating real-world scenarios, which makes personalized medical guidance essential when choosing between a GLP-1 RA and a dual-agonist option.

How Do You Decide?

First of all, you decide with your practitioner. It isn’t a decision anyone should be making on their own without proper medical guidance.

Weight loss is complex, and choosing the medication that appears most effective in clinical trials doesn’t always mean it’s the right fit for you. The therapy that is right for you is matched based on multiple factors: your body’s hormone response, metabolism, organ function, prior medication history, and potential drug interactions. Individual differences in gut hormone signaling and brain appetite pathways are part of the reason why two people on the same medication can have very different outcomes and even tolerability responses.

Baseline BMI and weight-related health conditions help determine eligibility and dosing. Co-existing health conditions, such as insulin resistance, cardiovascular risk, liver health concerns, or a history of gallbladder issues, influence which medication makes the most sense.

The ability to tolerate the medication and any potential side effects also impacts effectiveness. Some people adapt well. Others experience significant gastrointestinal symptoms when doses escalate too quickly and need slower titration schedules to improve tolerability. How someone starts the medication, and how well they are supported while taking it, make a difference. Ongoing nutritional guidance helps preserve lean muscle mass during weight loss, while behavioral support influences the sustainability of results once weight stabilizes.

At MIIS Wellness Institute, GLP-1 and GLP-1/GIP therapies are approached as part of a comprehensive metabolic strategy. If you’re curious which option aligns best with your physiology, goals, and health profile, a conversation with our team is an ideal next step.

1. Pi-Sunyer, Xavier, et al. “A Randomized, Controlled Trial of 3.0 Mg of Liraglutide in Weight Management.” New England Journal of Medicine, vol. 373, no. 1, 2 July 2015, pp. 11–22, www.nejm.org/doi/full/10.1056/NEJMoa1411892, https://doi.org/10.1056/nejmoa1411892.
2. Wilding, John P. H., et al. “Once-Weekly Semaglutide in Adults with Overweight or Obesity.” The New England Journal of Medicine, vol. 384, no. 11, 10 Feb. 2021, pp. 989–1002. PubMed, www.nejm.org/doi/full/10.1056/NEJMoa2032183, https://doi.org/10.1056/NEJMoa2032183.
3. Moiz, A., Filion, K. B., Tsoukas, M. A., Yu, O. H. Y., Peters, T. M., & Eisenberg, M. J. (2025). The expanding role of GLP-1 receptor agonists: a narrative review of current evidence and future directions. EClinicalMedicine, 86, 103363. https://doi.org/10.1016/j.eclinm.2025.103363.
4. Jakubowska, A., le Roux, C. W., & Viljoen, A. (2024). The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor – An Update. Endocrinology and Metabolism, 39(1), 12–22. https://doi.org/10.3803/enm.2024.1942.
5. Gallwitz, B. (2022). Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity. Frontiers in Endocrinology, 13. https://doi.org/10.3389/fendo.2022.1004044.